Biosimilars are a rapidly emerging segment in the global biopharmaceutical sphere. Explore the current biosimilar approval pathway in Canada, including Health Canada's recently proposed revisions to the guidance documents. Experts from Health Canada and industry will share an update on the biosimilars approved for marketing in Canada to date, along with some challenges these products have encountered. With litigation already heating up, hear from those involved on recent biosimilar proceedings that may frame the litigation landscape for biosimilars in Canada into the future.

PROGRAM CHAIRS

Geoffrey D. Mowatt, Dimock Stratton LLP (Chair, CBA Biotechnology Committee)               
Katharine McGinnis, McGinnis Law

AGENDA

To view the full program agenda, please click here.